Physician profile
Larry Good
NPI 1437134418
$13,094.24
in general payments reported to CMS, 2019-2025
39 companies · $2,256 in 2025
The $2,256 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $951 · 2021: $1,628 · 2022: $1,859 · 2023: $2,002 · 2024: $3,545 · 2025: $2,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,405 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,404.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,960.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,251.72 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $2,015.06 | 2019-2025 | |
| Janssen Biotech, INC. | $789.29 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $662.52 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $619.56 | 2022-2025 | Ibsrela |
| Celgene Corporation | $411.60 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $337.90 | 2021-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $319.37 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $234.99 | 2020-2025 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $234.77 | 2024-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $231.84 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $216.85 | 2019-2023 | Ocaliva |
| Astrazeneca Pharmaceuticals Lp | $184.31 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $183.23 | 2019-2025 | Repatha, Repatha |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $152.74 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Ipsen Biopharmaceuticals, INC | $102.06 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $101.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $93.82 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $91.71 | 2019-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $91.29 | 2020-2022 | |
| Tolmar, INC. | $84.96 | 2024-2025 | Jatenzo |
| Ethicon INC. | $78.31 | 2020-2023 | Monarch Platform |
| Zimmer Biomet Holdings, INC. | $75.98 | 2020-2023 | Ribfix Blu Advantage |
| Astellas Pharma US INC | $74.13 | 2020-2021 | |
| Novo Nordisk INC | $70.36 | 2019-2025 | Wegovy |
| Allergan, INC. | $52.74 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $52.14 | 2019-2020 | |
| Intra-Sana Laboratories | $52.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Kowa Pharmaceuticals America, INC. | $51.02 | 2020-2023 | Seglentis |
| Alfasigma USA, INC. | $42.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.28 | 2023 | Quviviq |
| Genzyme Corporation | $26.14 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.99 | 2021 | |
| Esperion Therapeutics, INC. | $22.60 | 2021 | |
| Medtronic, INC. | $20.70 | 2022 | |
| Lilly USA, LLC | $18.17 | 2024 | Zepbound, Omvoh |
| Janssen Pharmaceuticals, INC | $17.74 | 2022 | |
| Currax Pharmaceuticals LLC | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.